Matches in Nanopublications for { ?s ?p "DDI between Tiludronate and Magnesium oxide - The divalent cation of oral Magnesium oxide may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours. [drugbank_resource:DB01133_DB01377]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB01133_DB01377 label "DDI between Tiludronate and Magnesium oxide - The divalent cation of oral Magnesium oxide may significantly decrease the absorption of Tiludronate by forming a nonabsorbable chelate. Oral dosing should be separated by at least 2 hours. [drugbank_resource:DB01133_DB01377]" assertion.